Therapeutic Solutions International (TSOI) announced new data and filing of a patent covering the discovery that JadiCell therapeutic activity in a model of Chronic Obstructive Pulmonary Disease (COPD) can be transferred to naïve animals by a specialized type of B cell. These findings build upon previous discoveries of the company that specialized B cells, called “B regulatory cells”, correlate with patient response to stem cell therapy. In a series of experiments the Company found that B cell depletion abrogated therapeutic effects of JadiCell in a COPD model, and that transfer of a unique population of B cells to naïve mice was able to induce a protective effect.

Furthermore, antibody mediated blockade of the cytokine interleukin-35, was able to block therapeutic activity. In addition to the patent licensed from JadiCell, LLC (#9,803,176 B2), for respiratory indications, Therapeutic Solutions International has several patent applications pending and published covering the whole family of umbilical cord mesenchymal stem cells, to which JadiCell belongs to, for treatment of COPD2, as well as means of selecting for cells with enhanced activity.